Search
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalN-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. … It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnThe company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.
Measles virus vaccine live attenuated
go.drugbank.com/drugs/DB10315ApprovedInvestigationalThe vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
Products: Measles Virus Vaccine Live Atten DriedBumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis
Typhoid Vaccine Live
go.drugbank.com/drugs/DB11050ApprovedInvestigationalThe vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.
Methopterin
go.drugbank.com/drugs/DB16620InvestigationalMethopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.[A229843]
Cloprednol
go.drugbank.com/drugs/DB13843InvestigationalCloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. [A31775,A31776]
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.